Biologische Grundlagen einer Antikoagulantienbehandlung bei Tumorkrankheiten

L. R. Zacharski

doi:10.1055/s-0038-1655126

Hämostaseologie, Inhaltsverzeichnis

Hamostaseologie 1985; 05(05/06): 178-184
DOI: 10.1055/s-0038-1655126

Originalarbeiten

Schattauer GmbH

Biologische Grundlagen einer Antikoagulantienbehandlung bei Tumorkrankheiten

L. R. Zacharski

¹Department of Medicine, Dartmouth Medical School and the Veterans Administration Medical Center, White River Junction/USA

LITERATUR
1 Bastida E, Ordinas A, Jamieson G. A. Differing platelet aggregating effects by two tumor cell lines: absence of role for plateletderived ADP. Amer. J. Hematol. 11: 367-378 1981;
2 Billroth T. Lectures on Surgical Pathology and Therapeutics, translated from the. 8th. ed. London: New Sydenham Society; 1878
3 Brown J. M. A study of the mechanisms by which anticoagulation with warfarin inhibits blood borne metastasis. Cancer Res. 33: 1217-1224 1973;
4 Brugarolas A, Elias E. G, Takita H, Mink I. B, Mittelman A, Ambrus J. L. Blood coagulation and fibrinolysis in patients with carcinoma of the lung. J. Med. 04: 96-105 1973;
5 Byrd R. B, Divertie M. B, Spittell Jr. J. A. Bronchogenic carcinoma and thromboembolic disease. J. Am. Med. Assoc. 202: 1019-1022 1967;
6 Carmel R. J, Brown J. M. The effect of cyclophosphamide and other drugs on the incidence of pulmonary metastasis in mice. Cancer Res. 37: 145-151 1977;
7 Chahinian A. P, Ware J. H, Zimmer B, Comis R. L, Perry M. C, Hirsh V, Skarin A. T, Raich P. C, Weiss R. B, Green M, Carey R. W. Update on anticoagulation with warfarin and on alternating chemotherapy in extensive small cell carcinoma of the lung. Proc. Am. Soc. Clin. Oncol. 04: 191 1985;
8 Colucci M, Giavazzi R, Alessandri G, Semeraro N, Montavani A, Donati M. B. Procoagulant (tissue factor) activity is higher in cells from murine sarcoma sublines with lower metastatic pötentia. Thrombos. Haemostas. 46: 33 1981;
9 Delaini F, Colucci M, Vitti GDeBellis, Locati D, Poggi A, Semeraro N, Donati M. B. Cancer cell procoagulant: a novel vitamin K-dependent activity. Thromb. Res. 24: 263-266 1981;
10 Donati M. B, Poggi A, Semeraro N. Coagulation and malignancy. In: Recent Advances in Blood Coagulation. Vol. 3. Poller L. (Ed.). Churchill-Livingstone; New York: 1981: 227.
11 D’Souza D. P, Daly L, Thornes R. D. Increased survival in advanced breast cancer with warfarin, B. C. B. and levamisole as adjuvants to chemotherapy. Ir. Med. J. 71: 605-608 1978;
12 Dvorak H. F, Orenstein N. S, Dvorak A. M. Tumor-secreted mediators and the tumor microenvironment: relationship to immunologic surveillance. Lymphokines 02: 203-233 1981;
13 Edwards R. L, Rickles F. R, Cronlund M. Abnormalities of blood coagulation in patients with cancer. Mononuclear cell tissue factor generation. J. Lab. Clin. Med. 98: 917-928 1981;
14 Gilbert L, Gordon S. G. Relationship between cellular procoagulant activity and metastatic capacity of B-16 mouse melanoma variants. Cancer Res. 43: 536-540 1983;
15 Goerner A. The influence of anticlotting agents on transplantation and growth of tumor tissue. J. Lab. Clin. Med. 16: 369-372 1930;
16 Hagedorn A. B, Bowie E. J. W, Elvebach L. R, Owen Jr. C. A. Coagulation abnormalities in patients with inoperable lung cancer. Mayo Clin. Proc. 49: 647-653 1974;
17 Hara Y, Steinner M, Baldini M. B. Platelets as a source of growth-promoting factor(s) for tumor cells. Cancer Res. 40: 1212-1216 1980;
18 Henderson W. G, Zacharski L. R, Spiegel P. K, Rickles F. R, Forman W. B, Cornell Jr. C. J, Forcier R. J, Edwards R. L, Headley D, Kim S-H, O’Donnell J. F, O’Dell R, Tornyos K, Kwaan H. C. Comparison of local versus central tumor measurements in a multicenter clinical trial. Am. J. Clin. Oncol. 07: 705-712 1984;
19 Hilgard P, Thornes R. D. Anticoagulants in the treatment of cancer. Eur. J. Cancer 12: 755-762 1976;
20 Honn K. V, Busse W. D, Sloane B. F. Prostacyclin and thromboxanes. Implications for their role in tumor cell metastasis. Biochem. Pharmacol 32: 1-11 1983;
21 Jones D. S, Wallace A. C, Fraser E. E. Sequence of events in experimental metastases of Walker 256 tumor: light, immunofluorescent and electron microscopic observations. J. Natl. Cancer Inst. 46: 493-504 1971;
22 Karpatkin S, Pearlstein E. Role of platelets in tumor cell metastasis. Ann. Int. Med. 95: 636-641 1981;
23 Kepner N, Greasy G, Lipton A. Platelets as a source of cell proliferating activity. In: Platelets: A Multidisciplinary Approach. DeGaetano G, Garattini S. (Eds.). Raven Press; New York: 1978: 205.
24 Maat B, Hilgard P. Critical analysis of experimental models for the antimetastatic effects of anticoagulants. In: Clinical Experimental Aspects. Heilman K, Hilgard P, Eccles S. (Eds.). Martinus Nijhoff; Boston: 1980: 109-115.
25 Marcum J. M, McGill M, Bastida E, Ordinas A, Jamieson G. A. The interaction of platelets, tumor cells and vascular subendothelium. J. Lab. Clin. Med. 96: 1046-1053 1980;
26 O’Meara R. A. Q. Coagulative properties of cancers. Ir. J. Med. Sci. 06: 474-479 1958;
27 O’Meara R. A. Q, Jackson R. D. Cytological observations on carcinoma. Ir. J. Med. Sci. 06: 327-328 1959;
28 O’Meara R. A. Q. Fibrin formation and tumour growth. Thrombos. Diathes. Haemorrh. (Suppl) 28: 137-142 1968;
29 Onoda J. M, Sloane B. F, Taylor J. D, Honn K. V. Calcium channel blockers: inhibitors of tumor cell-platelet-endothelial cell interactions. In: Hemostatic Mechanisms and Metastasis. Honn K. V, Sloane B. F. (Eds.). Martinus Nijhoff; Boston: 1984: 244-258.
30 Pearlstein E, Salk P. L, Yogeeswaran G, Karpatkin S. Correlation between spontaneous metastatic potential, platelet aggregating activity of cell surface extracts and cell surface sialylation in 10 metastaticvariant derivatives of a rat renal sarcoma cell line. Proc. Natl. Acad. Sci. (USA) 77: 4336-4339 1980;
31 Pearlstein E, Cooper L. B, Karpatkin S. Extraction and characterization of a platelet-aggregating material from SV40-transformed mouse 3T3 fibroblasts. J. Lab. Clin. Med. 93: 332-334 1979;
32 Rickles F. R, Edwards R. L, Barb C, Cronlung M. Abnormalities of blood coagulation in patients with cancer. Fibrinopeptide A generation and tumor growth. Cancer 51: 301-307 1983;
33 Sack Jr. G. H, Levin J, Bell W. R. Trusseau’s syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical pathophysiologic and therapeutic features. Medicine 56: 1-37 1977;
34 Talmadge J. E, Starkey J. R, Stanford D. R. In vitro characteristics of metastatic variant subclones of restricted genetic origin. J. Supramol. Struct. Cell Biochem. 15: 139-151 1981;
35 Tanaka N, Ogawa H, Kinjo M, Kohga S, Tanaka K. Ultrastructural study of the effects of transexamic acid and urokinase on metastasis of Lewis lung carcinoma. Brit. J. Cancer 46: 428-435 1982;
36 Terranova T, Chiossone F. II fattore coagulazione neirattecchimento delle cellule neoplastiche immesse in circulo. Bull. Soc. Ital. Biol. Sper. 28: 1224-1225 1952;
37 Thornes R. D. Oral anticoagulant therapy of human cancer. J. Med. 05: 83-91 1974;
38 Thornes R. D. Adjuvant therapy of cancer via the cellular immune mechanism or fibrin by induced fibrinolysis and oral anticoagulants. Cancer 35: 91-97 1975;
39 Wessler S, Gitel S. N. Warfarin from bedside to bench. New Engl. J. Med. 311: 645-652 1984;
40 Wood Jr. S. Mechanism of establishment of tumor metastases. In: Pathobiology Annual. Joachim H. L. (Ed.). 1971: 281 281.
41 Zacharski L. R. Anticoagulation in the treatment of cancer in man. In: Malignancy and the Hemostatic System. Donati M. B, Davidson J. F, Garattini S. (Eds.). Raven Press; New York: 1981: 113-129.
42 Zacharski L. R. The biologic basis for anticoagulant treatment of cancer. In: Interaction of Platelets and Tumor Cells. Jamieson G. A. (Ed.). Alan R. Liss; New York: 1982: 113-127.
43 Zacharski L. R. Warfarin anticoagulation for human malignancy. In: Protective Agents in Cancer. McBrien D. C. H, Slater T. F. (Eds.). Academic Press; London: 1982: 23-36.
44 Zacharski L. R. The design and execution of anticoagulant therapy trials in cancer. In: Hemostatic Mechanisms and Metastasis. Honn K. V, Sloane B. F. (Eds.). Martinus Nijhoff; Boston: 1984: 375-392.
45 Zacharski L. R. Mechanisms of warfarin inhibition of cancer dissemination. In press 1985
46 Zacharski L. R, Henderson W. G, Rickles F. R, Forman W. B, Cornell Jr. C. S, Forcier R. J, Harrower H. W, Johnson R. O. Rationale and experimental design for the VA Cooperative Study of anticoagulation (warfarin) in the treatment of cancer. Cancer 44: 732-741 1979;
47 Zacharski L. R, Henderson W. G, Rickles F. R, Forman W. B, Cornell Jr. C. J, Forcier R. J, Headley E, Kim S-H, O’Donnell J. F, O’Dell R, Tornyos K, Kwaan H. C. Effect of sodium warfarin on survival in small cell carcinoma of the lung. J. Am. Med. Assoc. 145: 831-835 1981;
48 Zacharski L. R, Henderson W. G, Rickles F. R, Forman W. B, van Eeckhout J. P, Cornell Jr. C. J, Forcier R. J, Martin J. F. Platelets and malignancy: rationale and experimental design for the VA Cooperative Study of RA-233 in the treatment of cancer. Amer. J. Clin. Oncol. 05: 593-609 1982;
49 Zacharski L. R, Henderson W. G, Rickles F. R, Forman W. B, Cornell Jr. C. J, Forcier R. J, Edwards R. L, Headley E, Kim S. H, O’Donnell J. F, O’Dell R, Tornyos K, Kwaan H. C. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate: final report of VA Cooperative Study # 75. Cancer 53: 2046-2052 1984;
50 Zacharski L. R, Schned A. R, Sorenson G. D. Occurrence of fibrin and tissue factor antigen in human small cell carcinoma of the lung. Cancer Res. 43: 3963-3968 1983;
51 Zacharski L. R, Rosenstein R. Reduction of salivary tissue factor (thromboplastin) activity by warfarin therapy. Blood 53: 366-374 1979;